Amgen Posts Strong Q2 Results and Regulatory Momentum, Driving AMGN Stock Higher

Amgen (NASDAQ: AMGN) released its second-quarter 2026 earnings on August 4, revealing momentum across its portfolio that contributed to a positive investor response in the past week.

In Q2, Amgen reported total revenue of $10.1 billion, up 10% year‑over‑year, with product sales increasing 9%, driven by volume growth. GAAP earnings per share climbed sharply from $2.65 to $4.37—a 65% increase. Non‑GAAP EPS also rose to $6.29, up 4%. These results were supported by strong contributions from multiple products, including Repatha (+37%), Evenity (+38%), Uplizna (+90%), and Tezspire (+42%), while legacy franchises like Prolia and Enbrel experienced declines tied to biosimilar competition and pricing pressures. Free cash flow doubled to $3.5 billion from $1.9 billion a year earlier. (Reported August 4; Amgen press release)

Shortly after, on August 18, news surfaced that the European regulator’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending broader use of Repatha before a first heart attack or stroke—setting the stage for potential label expansion in the EU. (Reported July 29; Amgen press release)

Another key development involves TAVNEOS, Amgen’s therapy for ANCA‑associated vasculitis. On July 23, the company submitted supporting materials to the FDA in response to the agency’s request to voluntarily withdraw TAVNEOS from the U.S. market. Amgen believes the data demonstrate a favorable benefit‑risk profile and has formally requested a hearing. (Amgen press release)

These developments appear to have contributed to the stock’s recent strength. In the week ending August 7, AMGN gained 6.7%, trading around $410.95. The following week peak reached as high as $421.79 on August 11, marking a string of 30‑day highs. (Weekly data through August 7 and mid‑August trading highs; weekly equity report and historical price data)

Why It Matters

The Q2 beat across earnings, revenue, and cash flow underlines Amgen’s operational resilience amid biosimilar headwinds. Double‑digit growth in key products like Repatha, Uplizna, and Tezspire demonstrates successful execution of the company’s growth strategy, contributing nearly 70% of product sales and indicating a durable growth roadmap.

The CHMP’s positive opinion toward expanded Repatha use could unlock substantial market opportunity in Europe by positioning the therapy earlier in cardiovascular risk management. Meanwhile, Amgen’s pushback on the FDA’s TAVNEOS withdrawal request suggests the company is prioritizing life‑cycle management and rare disease treatment continuity.

What Investors Should Monitor

• Outcome of the FDA hearing or any further response regarding the U.S. status of TAVNEOS.
• European Commission’s final decision on the CHMP’s Repatha recommendation.
• Upcoming data releases—especially Repatha analyses slated for the European Society of Cardiology (ESC) Congress in August highlighting expanded cardiovascular benefit.

With AMGN’s stock price holding robustly above $420 following these developments, the company’s clear delivery on financials and ongoing regulatory catalysts may continue lifting investor sentiment in the near term.